Capítulo 7.2. Nefropatía tóxica

Bibliografía
 

1. Cohen AJ, Clive DM. Acute renal failure in the intensive care unit. En: Rippe JM, Irwin RS, Fink MP, Cerra FB, ed. Intensive care medicine. 3ª ed. Boston: Little, Brown and Co., 1996: 1000-22. 
2.  Tonnesen AS. Acute renal failure. En: Gallagher TJ, Shoemaker WC, ed. Critical care. State of the art. Vol. 9. Fullerton: Society of Critical Care Medicine, 1988: 177-222.
3. Pellanda MV, Fabris A, Ronco C. Etiology and pathophysiology of acute renal failure. En: Pinsky MR, Dhainaut JF, ed. Pathophysiologic foundations of critical care. Baltimore: Williams & Wilkins, 1993: 571-85.
4. Hock R, Anderson RJ. Prevention of drug-induced nephrotoxicity in the intensive care unit. J Crit Care 1995; 10: 33-43.
5. Cronin RE, Henrich WL. Toxic nephropathy. En: Brenner BM, ed. Brenner and Rector’s. The kidney. 5ª ed. Philadelphia: WB Saunders Co., 1996: 1680-1711.
6. Muther RS. Acute renal failure: acute azotemia in the critically ill. En: Civetta JM, Taylor RW, Kirby RR, ed. Critical care. 2ª ed. Philadelphia: J.B. Lippincott Co., 1992: 1583-97. 
7. Molitoris BA. New insights into the cell biology of ischemic acute renal failure. J Am Soc Nephrol 1991; 1:1263-70.
8. Brezis M, Rosen S, Silva P, et al. Polyene toxicity in renal medulla: Injury mediated by transport activity. Science 1984; 224: 66-68.
9. Stillman IE, Brezis M, Greenfeld Z, et al. Cyclosporine nephropathy: Morphometric analysis of the medullary thick ascending limb. Am J Kidney Dis 1992; 20:162-167.
10. Heyman SN, Brezis M, Greenfeld Z, et al. Protective rol of furosemide and saline in readiocontrast-induced acute renal failure in the rat. Am J Kidney Dis 1989; 14:377-85.
11. Pérez R., Valderrábano F. Nefropatías tubulointersticiales. En Martínez M, Rodicio JL, Herrera J, ed. Tratado de nefrología. 2ª ed. Madrid: Ediciones Norma SL., 1993: 900-36. 
12. Nolan CR, Kelleher SP. Eosinophiluria. Clin Lab Med 1988; 8:555-65.
13. Kelly J, Neilson G. Tubulointerstitial diseases. En Brenner BM, ed. Brenner and Rector’s. The Kidney. 5ª ed. Philadelphia: WB Saunders Co., 1996: 1655-79.
14. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35: 1257-70.
15. Laberke HG, Bohle A. Acute interstitial nephritis: Correlations between clinical and morphological findings. Clin Nephrol 1980; 14: 263-73.
16. Appel GB, Kunis CL. Acute tubulointerstitial nephritis. En: Cotran RS, ed. Tubulointerstitial nephropathies. New York: Churchill Livingstone,  1983:151-185.
17. Walshe JJ, Venuto RC. Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 1979; 91: 47-49.
18. Margulies KB, Hildebrand FL, Heublein DM; et al. Radiocontrast increases plasma and urinary endothelin. J Am Soc Nephrol 1991; 2: 1041-45.
19. Hricik DE; Dunn MJ. Angiotensin-converting enzyme inhibitor-induced renal failure: Causes, consequences, and diagnostic uses. J Am Soc Nephrol 1990; 1: 845-58
20. Honda N, Kurokawa K. Acute renal failure and rhabdomyolysis. Kidney Int 1983; 23: 888-98
21. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89: 630-39.
22. Holland  MD, Galla JH, Sanders PW, et al. Effect of urinary pH and diatrizoate on Bence-Jones protein nephrotoxicity in the rat. Kidney Int 1985; 27:46-50.
23. Sanders PW, Booker BB, Bishop JB, et al. Mechanism of intranephronal proteinaceus cast formation by low molecular weight proteins. J Clin Invest 1990; 85:570-76. 
24. Nolan CM, Abernathy RS. Nephrophaty associated with methicillin therapy. Prevalence and determinants in patients with staphylococcal bacteremia. Arch Intern Med 1977; 137: 997-1000.
25. Leehey DJ, Braun BI; Tholl DA, et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 1993; 4: 81-90.
26. Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Inf Dis 1993; 167:173-79.
27. Ford DM, Dahl RH, Lamp CA, et al. Apically and basolaterally internalized aminoglycosides colocalize in LLCPK1 lysosomes and alter cell function. Am J Physiol 1994; 266:52-57.
28. Appel GB. Aminoglycoside nephrotoxicity. Am J Med 1990; 88: 16-20.
29. Appel GB, Given DB, Levin LR, et al. Vancomycin and the kidney. Am J Kid Dis 1986; 8: 75-80.
30. DeBroe ME, Giuliano RA, Verpooten GA: Choice of drug and dosage regimen: Important factors for aminoglycoside nephrotoxicity. Am J Med 1986; 80 6B:115-118.
31. Tulkens PM. Experimental studies on nephrotoxicity of aminoglycosides at low doses. Am J Med 1986; 80: 105-14.
32. Quinn BM, Wall BM. Nephrogenic diabetes insipidus and tubulointerstitial nephritis during continous therapy with rifampin. Am J Kidney Dis 1989; 14: 217-20.
33.  Power DA, Russell G, Smith FW, et al. Acute renal failure due to continous rifampicin. Clin Nephrol 1983; 20:155-59.
34.  Sokol PP. Mechanism of vancomycin transport in the kidney: studies in rabbit renal brush border and basolateral membrane vesicles. J Pharmacol Exp Ther 1991; 259:1283-87.
35. Farber BF, Moellering RC. Retrospective  study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138-41.
36. Cheng JT, Witty RT, Robinson RR, et al. Amphotericin B nephrotoxicity: Increased renal resistance and tubule permeability. Kidney Int 1982; 22:626-33.
37. Heyman SN, Clark BA, Kaiser N, et al. In-vivo and in-vitro studies on the effect of amphotericin B on endothelin release. J Antimicrob Chemother 1992; 29:69-77.
38. Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocysti carinii pneumonia in the acquired inmunodeficiency syndrome. Ann Intern Med 1988; 109:280-87.
39. Antoniskis D, Larsen RA. Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 1990; 34: 470-72.
40. Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure. Clinical course and histology. Am J Med  1988; 84:1067-71.
41. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am J Nephrol 1989; 9:316-21.
42. Anderson RJ, Berl T, McDonald KM, et al. Prostaglandins: Effects on blood pressure renal blood flow, sodium and water excretion. Kidney Int 1976; 10: 205-15.
43. DuBose TD, Molony DA, Verani R, et al. Nephrotoxicity of non-steroidaal anti-inflammatory drugs. Lancet 1994; 344:515-18.
44. Blackshear JS, Davidman M, Stillman T. Identification of risk for renal insufficiency from NSAIDS. Arch Int Med 1983; 143: 1130-34.
45. Feinfeld DA, Olesnicky L, Pirani CL, et al. Nephrotic syndrome associated with use the nonsteroideal anti-inflammatory drugs. Case report and review of the literature. Nephron 1984; 37: 174-199.
46. Mongestern SJ, Bruns FJ, Fraley DS, et al. Ibuprofen-associated lipoid nephrosis without interstitial nephritis. Am J Kidney Dis 1989; 14: 50-52.
47. Kleinknecht D. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15: 228-35.
48. Segasothy M, Samad SA, Zulfigar A, et al. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroideal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994; 24: 17-24. 
49. Aitken HA, Burns JW, McArdle CS, et al. Effects of ketorolac trometamol on renal function. Br J Anaesth 1992; 68: 481-85.
50. Perazalla MA, Buller GK. NSAID nephrotoxicity revisited: Acute renal failure due to parenteral ketorolac. South Med J 1993; 86: 1422-24.
51. Haragsim L, Dalal R, Bagga H, et al. Ketorolac-induced acute renal failure and Hyperkalemia: report of three cases. Am J Kidney Dis 1994; 24: 578-80.
52. Fong J, Gora ML. Reversible renal insufficiency following ketorolac therapy. Ann Pharmacother 1993; 27: 510-12.
53. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. Arch Intern Med 1990; 150: 1237-42.
54. Barrett BJ, Carslile EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality contrast media. Radiology 1993; 188: 171-78.
55. Cigarroa RG, Lange PA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86: 649-58.
56. Barrett BJ. Contrast nephrotoxicity (editorial). J Am Soc Nephol 1994; 5: 125-37.
57. Cantley LG, Spokes K, Clark B, et al. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993; 44: 1217-23.
58. Berns AH. Nephrotoxicity of contrast media. Kidney Int 1989; 36: 730-40.
59. Weisberg LS, Kurnik PB, Kurnik BR. Risk of  radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259-65.
60. Kon V, Sugiura M, Inagami T, et al. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37:1487-91.
61. Wagner K, Henkel M, Heinemeyer G, et al. Interaction of calcium blockers and cyclosporine. Trasplant Proc 1988 20 (suppl 2):561-68.
62. Dawidson Y, Rooth P, Alway C, et al. Verapamil prevents post-transplant delayed function and cyclosporine A nephrotoxicity. Transplant Proc 1990; 22: 1379-80. 
63. Pirsch JD, D’Alessandro AM, Roecker EB, et al. A controlled double-blind, randomized trial of verapamil cyclosporine in cadaver renal transplant patients. Am J Kidney Dis 1993; 21: 189-95.    
64. Textor SC, Wiesner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK 506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332-39.
65. Memoli B, De Nicola L, Libetta C, et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis 1995; 26: 27-33.
66. Siegel JP, Puri RK. Interleukin 2 toxicity. J Clin Oncol 1991; 9: 694-704.
67. Henrich WL. Functional and organic ischemic renal disease. En: Seldin DW, Giebisch GH, ed. Physiology and Pathophysiology, 2nd ed. New York: Raven Press, 1992: 3289-304.